Note at the end of the Nature article that Ndhlovu, a member of the CYDY advisory board, is also an advisor to Abbvie and ViiV. Mind you, ViiV and Gilead pretty much own the HIV space, so if there was anyone we would want on our team, it's him. Make a mental note, his involvement has been/is/will be absolutely critical to the advancement of LL in HIV.